China News Service, May 6 (Reporter Chen Jing) The reporter learned on the 6th that the precision targeting drug Taijihua® (Avatinib) for gastrointestinal stromal tumors (GIST) has widely benefited Chinese patients. Bring new options for treatment.
It is reported that nearly 30 hospitals, including Peking University Cancer Hospital, Peking University People's Hospital, and Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, simultaneously issued the first batch of prescriptions for this innovative drug.
Relevant pharmaceutical companies supply medicines to more than 50 hospitals and out-of-hospital pharmacies in many provinces and cities in China.
Gastrointestinal stromal tumor (GIST) is a sarcoma that occurs in the gastrointestinal tract. Some cases are caused by the PDGFRA D842V mutation. Such patients have been lacking therapeutic drugs.
Not long ago, Taijihua® (Avatinib Tablets), a precision targeted drug for gastrointestinal stromal tumor (GIST), was approved for marketing by the State Drug Administration of China.
Taijihua® has issued prescriptions in many places in China.
Photo by Wang Xia
Professor Ye Yingjiang, Director of Gastrointestinal Surgery, Peking University People’s Hospital, and Cao Hui, Director of General Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, both stated in an interview with reporters on the 6th that Taijihua® will issue prescriptions for GIST in many places in China. Patient treatment provides new options to further help patients improve their prognosis and improve their quality of life.
In an interview on the 6th, the main researcher of avatinib in China, Professor Lin Lin, deputy dean of Peking University Cancer Hospital, said that for many years, the public awareness and social attention of gastrointestinal stromal tumors have been relatively low.
There is an urgent need for precision drugs to prolong the survival of patients with PDGFRA D842V mutation.
It is understood that the onset of GIST is insidious and easy to be ignored by routine testing methods. Patients are often in the middle and advanced stages when they are diagnosed, and the primary drug resistance mutations and the progression of drug resistance after multi-line targeted therapy make GIST patients have treatment. There is a huge unmet need.
The results of clinical studies showed that the overall remission rate of avatinib reached 62.5%.
Professor Lin Shen said: “Avatinib has shown very good anti-tumor activity in patients with related types of advanced GIST in China, and it is safe and well tolerated.” Professor Lin Lin said that Taijihua® is available in mainland China The landing of the prescription of the drug is of great significance to improving the current status of domestic GIST treatment.
The reporter learned on the same day that Shanghai’s "Rational Use of Drugs Promotion Month" will be launched on the 6th in 2021.
The Shanghai Medical Doctor Association has established a clinical rational drug use professional committee jointly participated by front-line backbone physicians and pharmacists to continuously improve the professional skills of physicians and pharmacists in rational drug use.
It is reported that since 2016, Shanghai has designated May every year as the "Rational Use of Drugs Promotion Month." Over the past five years, more than 70,000 medical staff have participated in activities related to the "Rational Use of Drugs Promotion Month". Over the years, more than 240 community health service centers in Shanghai have established "clinical pharmacy paired assistance relationships" with 19 municipal hospitals and 55 district hospitals, aiming at the weaknesses of community health service centers in pharmacy management and pharmacy services. Links to enhance the ability of primary pharmacy services. (Finish)